Effect of ACAT inhibition on the progression of coronary atherosclerosis.

BACKGROUND The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) esterifies cholesterol in a variety of tissues. In some animal models, ACAT inhibitors have antiatherosclerotic effects. METHODS We performed intravascular ultrasonography in 408 patients with angiographically documented coronary disease. All patients received usual care for secondary prevention, including statins, if indicated. Patients were randomly assigned to receive the ACAT inhibitor pactimibe (100 mg per day) or matching placebo. Ultrasonography was repeated after 18 months to measure the progression of atherosclerosis. RESULTS The primary efficacy variable analyzing the progression of atherosclerosis--the change in percent atheroma volume--was similar in the pactimibe and placebo groups (0.69 percent and 0.59 percent, respectively; P=0.77). However, both secondary efficacy variables assessed by means of intravascular ultrasonography showed unfavorable effects of pactimibe treatment. As compared with baseline values, the normalized total atheroma volume showed significant regression in the placebo group (-5.6 mm3, P=0.001) but not in the pactimibe group (-1.3 mm3, P=0.39; P=0.03 for the comparison between groups). The atheroma volume in the most diseased 10-mm subsegment regressed by 3.2 mm3 in the placebo group, as compared with a decrease of 1.3 mm3 in the pactimibe group (P=0.01). The combined incidence of adverse cardiovascular outcomes was similar in the two groups (P=0.53). CONCLUSIONS For patients with coronary disease, treatment with an ACAT inhibitor did not improve the primary efficacy variable (percent atheroma volume) and adversely affected two major secondary efficacy measures assessed by intravascular ultrasonography. ACAT inhibition is not an effective strategy for limiting atherosclerosis and may promote atherogenesis. (ClinicalTrials.gov number, NCT00268515.).

[1]  J. Sahi,et al.  Avasimibe Induces CYP3A4 and Multiple Drug Resistance Protein 1 Gene Expression through Activation of the Pregnane X Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.

[2]  R H Selzer,et al.  Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. , 1996, Circulation.

[3]  J. Badimón,et al.  Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E—Deficient Mice , 2001, Circulation.

[4]  E. Tuzcu,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease , 2005 .

[5]  T. Bocan,et al.  Inhibition of acyl-CoA cholesterol O-acyltransferase reduces the cholesteryl ester enrichment of atherosclerotic lesions in the Yucatan micropig. , 1993, Atherosclerosis.

[6]  D. Small,et al.  Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[7]  O. Press,et al.  Translocation of Ricin A-chain into Proteoliposomes Reconstituted from Golgi and Endoplasmic Reticulum (*) , 1995, The Journal of Biological Chemistry.

[8]  S. Perrey,et al.  Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. , 2001, Atherosclerosis.

[9]  M. Willingham,et al.  Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates. , 2000, Journal of lipid research.

[10]  D G Vince,et al.  Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. , 2001, Journal of the American College of Cardiology.

[11]  T. Craven,et al.  Prognostic Significance of Progression of Coronary Atherosclerosis , 1993, Circulation.

[12]  W. J. Johnson,et al.  Cell Toxicity Induced by Inhibition of Acyl Coenzyme A:Cholesterol Acyltransferase and Accumulation of Unesterified Cholesterol * , 1995, The Journal of Biological Chemistry.

[13]  Robert V Farese,et al.  Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. , 2000, The Journal of clinical investigation.

[14]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[15]  Fernando Alfonso,et al.  Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions , 2004, Circulation.

[16]  T. Major,et al.  The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[17]  B. R. Krause,et al.  ACAT-2, A Second Mammalian Acyl-CoA:Cholesterol Acyltransferase , 1998, The Journal of Biological Chemistry.

[18]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[19]  Bruce R. Brodie,et al.  Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial , 2004 .

[20]  B. Auerbach,et al.  The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. , 2001, Atherosclerosis.

[21]  C. Tracy,et al.  American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2001, Journal of the American College of Cardiology.

[22]  J. Jukema,et al.  Its Cholesterol-Lowering Effect in ApoE * 3-Leiden Mice Acyl-CoA : Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to , 2001 .

[23]  T. Heinonen.  Inhibition of acyl coenzyme a-cholesterol acyltransferase: A possible treatment of atherosclerosis? , 2002, Current atherosclerosis reports.

[24]  E. Tuzcu,et al.  Variability of area measurements obtained with different intravascular ultrasound catheter systems: Impact on clinical trials and a method for accurate calibration. , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[25]  M. Yamasaki,et al.  Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits. , 1998, Japanese journal of pharmacology.

[26]  S. Horiuchi,et al.  Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[27]  P. Libby,et al.  Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .

[28]  I. Tabas,et al.  ABCA1-mediated Cholesterol Efflux Is Defective in Free Cholesterol-loaded Macrophages , 2002, The Journal of Biological Chemistry.

[29]  Robert V Farese,et al.  Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. , 2001, The Journal of clinical investigation.

[30]  S. Horiuchi,et al.  Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis. , 2003, Current opinion in investigational drugs.

[31]  Ira Tabas,et al.  Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. , 2002, The Journal of clinical investigation.

[32]  R. Nicolosi,et al.  Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys. , 1994, Journal of lipid research.

[33]  Peter Libby,et al.  The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.